This research reviews how vaccines other than for travel or influenza are evaluated, procured and delivered in the UK. It includes observations as to whether and how the economic assessment process differs for vaccines compared to curative pharmaceutical products and the implications of the current pricing approach.
Mestre-Ferrandiz, J., Puig-Peiro, R. and Towse, A.
Ten member companies of the EFPIA HTA Task Force commissioned OHE consulting to provide research, data and analysis that would enable EFPIA both to support and develop its policy position and to contribute positively to the emerging dialogue around the development of HTA within Europe.
The debate continues as to whether public/charitable research replaces private research that otherwise would have occurred, or stimulates additional private research, or does neither. Given the extent of public and charitable biomedical research, the debate is particularly intense.
Garau, M., Shah, K., Towse, A., Wang, Q., Drummond, M.F. and Mason, A. R.
Lower usage of cancer medicines in the UK compared to other countries has created questions, including whether the current approach by NICE to assessing cancer medicines is an important factor in lower use in the UK. This Report is based on both a detailed literature review and interviews with key experts directly involved in the work of UK HTA bodies.
Health Economics Research Group, Office of Health Economics and RAND Europe.
Understanding the nature, extent and processes involved in the return on investment in medical research has been largely neglected as an area of serious scientific study. This report is the outcome of a one-year study commissioned by the UK Academy of Medical Sciences, the UK Medical Research Council and the Wellcome Trust. Its purpose is to compare the economic benefits accruing in the UK from medical research funded in the UK, publicly or by charities only, to the cost of that research.